Question · Q4 2025
Joel Jackson requested a detailed breakdown of 2026 revenue guidance for specific product buckets, including Rynaxypyr (partnered and non-partnered), non-Rynaxypyr core, Cyazypyr, and Plant Health, compared to 2025.
Answer
Andrew Sandifer, EVP and CFO, indicated that Rynaxypyr partner sales are expected to decline due to volume and price, while the legacy core portfolio will see a slight contraction. He confirmed growth across all aspects of the growth portfolio, led by new active ingredients, Cyazypyr, and Plant Health. Pierre Brondeau, Chairman, CEO and President, reiterated that all parts of the growth portfolio are growing, and branded Rynaxypyr earnings are targeted to be flat.
Ask follow-up questions
Fintool can predict
FMC's earnings beat/miss a week before the call


